ReviewDeutsches Arzteblatt international2026
Rabies in Europe: Epidemiology, Clinical Management, and Prevention.
Review in Deutsches Arzteblatt international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prevention of neuroinfectious-diseases: high impact of vaccination programs - but the potential is not maxed out yet.Neurological research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRabies is one of the oldest known zoonoses. In Europe, because cases are rare and medical experience is limited, there is often uncertainty about the indications and modalities of pre- and post-exposure prophylaxis (PrEP, PEP).
methodsThis review is based on studies of the epidemiology, diagnosis, treatment, and prophylaxis of rabies that were published from January 2000 to October 2025 and retrieved by a selective search in PubMed, supplemented by data from the WHO, CDC, ECDC, RKI, and FLI and the current recommendations of the German Standing Committee on Vaccination (STIKO).
resultsThe WHO reports that approximately 60 000 persons die of rabies each year around the world, mainly in southern Asia and Africa, and that dogs are the source of the infection in more than 99% of cases. Once the disease has become manifest, its lethality is nearly 100%. Terrestrial rabies is considered to have been largely eliminated in the member states of the European Union (EU) since 2008, although zoonotically relevant bat lyssaviruses are still being regularly documented. As a result, even in Germany, a low risk of infection remains through contact with bats and through importation of infected animals from endemic areas abroad. The use of modern cell-culture vaccines for PrEP yields protection rates of 96-100%, with rare severe side effects (< 1:10 000). PEP is highly effective: after its administration in more than 29 million cases per year around the world from 1980 to 2022, only 122 breakthrough infections were registered, mainly because of faulty administration of rabies immunoglobulin, inadequate wound cleansing, and a late start of PEP. The main preventive measures are PrEP, avoidance of exposure, rapid wound disinfection, early PEP, and counseling by specialists in travel medicine.
conclusionDespite the favorable epidemiological situation, the possibility of rabies should be considered early on for anyone in Europe who has had an unclear animal exposure-especially to bats-or a potential rabies exposure abroad. When questions remain about the indication or modalities of PEP, expert advice should be obtained from an infectious disease unit or a rabies information center.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.